$15.07
-0.01 (-0.07%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+333.05%
1Y
+939.31%
YTD
+319.78%
Open$14.84
Previous Close$15.08
Day High$15.75
Day Low$14.76
52W High$24.28
52W Low$1.21
Volume—
Avg Volume4.91M
Market Cap4.25B
P/E Ratio—
EPS$-0.93
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$7.48
Above
SMA 200
$3.25
Above
RSI (14)
71.9
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
17 analysts
Price Target
+63.6% upside
Current
$15.07
$15.07
Target
$24.65
$24.65
$19.75
$24.65 avg
$31.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 897.62M | 918.48M | 827.43M |
| Net Income | -100,463,137 | -95,918,574 | -115,001,691 |
| Profit Margin | -11.2% | -10.4% | -13.9% |
| EBITDA | -104,291,949 | -115,509,109 | -110,721,792 |
| Free Cash Flow | -130,963,293 | -137,514,931 | -125,568,165 |
| Rev Growth | +16.3% | +1.8% | +8.3% |
| Debt/Equity | 0.25 | 0.25 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |